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Abstract Parkinson’s disease psychosis (PDP) is a con-
dition that may develop in up to 60 % of Parkinson’s
patients, and is a major reason for nursing home placement
for those affected. There are no FDA approved drugs for
PDP but low doses of atypical anti-psychotic drugs (APDs)
are commonly prescribed off-label. Only low-dose cloza-
pine has shown efficacy in randomized controlled trials, but
all APDs have black box warnings related to the increased
mortality and morbidity when used in elderly demented
patients. Using molecular pharmacological profiling of a
large collection of marketed drugs, we discovered that
potent inverse agonist activity against 5-HT2A serotonin
receptors was a common feature of atypical APDs, espe-
cially the atypical APDs used to treat PDP. Since low-dose
clozapine therapy selectively blocks this receptor, it was
hypothesized that a highly selective 5-HT2A receptor
inverse agonist might provide good symptom control in
patients suffering from PDP, with a greatly improved
safety and tolerability profile. A high throughput screening
and subsequent chemical lead optimization campaign to
develop potent, selective 5-HT2A receptor inverse agonists
was launched, eventually resulting in the discovery of
pimavanserin. Pimavanserin displays nanomolar potency
as a 5-HT2A receptor inverse agonist, selectivity for
5-HT2A over 5-HT2C receptors, and no meaningful activity
at any other G-protein coupled receptor. It demonstrated
robust activity in preclinical models of schizophrenia and
PDP, and did not worsen motoric symptoms, in contrast to
the APDs tested. In a Phase III clinical trial, pimavanserin
showed highly significant benefits in the primary endpoint,
the scale for assessment of positive symptoms-PD, a scale
adapted for use in PDP. In addition, improvements in all
other efficacy endpoints, including physician’s clinical
global impression, caregiver burden, night-time sleep
quality and daytime wakefulness, were seen. Pimavanserin
demonstrated good safety and tolerability and did not
worsen motoric symptoms as assessed by the unified Par-
kinson’s disease rating scale parts II and III. An open-label
extension study has further demonstrated that pimavanserin
is safe and well-tolerated with long-term use. Pimavanserin
may therefore offer a viable treatment option for patients
suffering from PDP.
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Background
Parkinson’s disease (PD) is a neurodegenerative disease
that affects millions of people worldwide. PD is more
common in older people and the number of PD patients is
expected to increase with the increasing age of the
worldwide population. The most obvious symptoms of PD
are motoric and include tremor, bradykinesia, rigidity, and
disturbed balance and posture. The motor symptoms in PD
are directly related to the progressive degeneration of pri-
marily brain dopamine (DA) neurons. No disease modify-
ing drugs have yet been developed for PD and various
symptomatic drugs are currently used to treat the motor
symptoms of the disease. These drugs include DA receptor
agonists, MAO inhibitors, L-DOPA and amantadine [1].
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While motor symptoms of PD used to be the focus of
treatment, it has now been realized that non-motor symp-
toms are equally disturbing to the patient [2]. The most
common non-motor symptoms include depression, sleep
problems, psychosis and dementia. Parkinson’s disease
psychosis (PDP) [3, 4], which is characterized by halluci-
nations and/or delusions, may develop in up to 60 % of PD
patients [5], is persistent and progressive and associated
with deterioration in quality of life as well as increased
morbidity and mortality. Psychosis has been identified as
the leading cause of nursing home placement among PD
patients [6]. Currently, there is no effective, tolerated and
safe therapy available for treatment of PDP. While low
doses of clozapine are approved as a second line therapy in
Europe, no first-line therapy is available and no PDP drug
is approved in any other major market.
There are many marketed anti-psychotic drugs (APDs) but
they all block the dopamine (DA) D2 receptors which are the
target for the symptomatic DA replacement therapy in PD.
Hence, they are pharmacologically contraindicated for PD
and at effective antipsychotic doses these drugs induce
intolerable motor side effects in PD patients. There is one
exception: clozapine, which is used to treat schizophrenia in
daily doses from 300 to 900 mg, is tolerated and effective in
treating the psychosis in PDP patients when given at more than
10 fold lower doses than used in schizophrenia therapy [7, 8].
Despite the clinical evidence for efficacy and tolerability
of clozapine in PDP therapy, it is infrequently used. There are
two major problems with clozapine therapy in PDP: First,
clozapine is not safe, even at the low doses used for PDP. It
may still cause agranulocytosis [9] and, thus, requires fre-
quent blood monitoring. Second, the histamine H1 antago-
nism of clozapine leads to sedation. This adds to the
excessive daytime sleepiness seen in PD patients. Rather
than using clozapine, neurologists tend to resort to using
quetiapine for managing PDP [10]. Unfortunately, while low
doses of quetiapine are motorically tolerated by patients,
these low doses have not demonstrated efficacy [11] and still
are associated with excessive sedation. In addition, like all
other marketed APDs, clozapine and quetiapine have a black
box warning for use in elderly demented patients with psy-
chosis due to increased mortality and morbidity.
The low doses of clozapine which have shown efficacy in
PDP are likely to selectively block only 5-HT2A and H1
receptors and do not appear to block the brain DA D2
receptors [12, 13]. Since H1 receptor antagonism is known to
produce sedation but is unlikely to contribute to the anti-
psychotic effect of clozapine, the effectiveness of low-dose
therapy with clozapine in PDP suggests that 5-HT2A receptor
blockade is the relevant target mechanism [14]. More recent
data from a PET study in patients provide additional evi-
dence for the importance of the 5-HT2A receptor in PDP by
demonstrating that visual hallucinations in PD are correlated
with excessive 5-HT2A neurotransmission [15].
The Discovery of Pimavanserin
In the late 1990s ACADIA scientists started a chemical
genomics effort aimed at improving the understanding of the
targets for drugs acting on the central nervous system [16]. A
comprehensive library of marketed CNS drugs were evalu-
ated for activity on a wide range of G-protein coupled
receptors (GPCRs) using the Receptor Selection and
Amplification TechnologyTM (R-SATTM) platform, a high-
throughput functional assay technology that is well suited
for chemical genomics and high-throughput screening
(HTS), and is applicable to a wide array of genetic targets
including most GPCRs, receptor tyrosine kinases, cytokine
receptors, and nuclear receptors [17]. R-SATTM utilizes the
principles of genetic selection and is based on the observa-
tion that oncogenes and many receptors induce proliferation
or transformation responses in NIH-3T3 cells. Agonists
preferentially select and amplify cells that express func-
tional receptors. In cases where the genetic target exhibits
constitutive activity, cellular proliferation occurs in the
absence of added agonists. In such cases, inverse agonists
can be readily identified by their ability to suppress prolif-
erative responses [18–21]. Typically, the optimal signal is
observed 5–6 days post-transfection, a period of time during
which the reporter is amplified in the proliferating cells and
diminished in the quiescent cells [22].
GPCRs frequently possess some degree of ligand inde-
pendent or constitutive activity [23]. Of the various func-
tional assays used for HTS, RSATTM may provide the most
sensitive means of detecting constitutive activity, possibly
due to its assay length of 5–6 days which allows for
amplification of constitutive responses to occur. For
example, a direct comparison of calcium flux, phosphatidyl
inositol hydrolysis (PI) and R-SATTM assays reveals the
constitutive activity of the Ghrelin receptor is most easily
detected using R-SATTM [17]. These findings strongly
agree with a previous study in which the constitutive
responses of wild-type and mutant forms of the 5-HT2A
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receptor were much more apparent using R-SATTM assays
compared with PI assays [24].
While screening numerous typical and atypical APDs, we
discovered that most of the atypical APDs, including clo-
zapine, had one activity in common which separated them
from the typical antipsychotic agents. They were potent and
fully efficacious inverse 5-HT2A agonists [25] and they were
less or much less potent as DA D2 receptor antagonists. The
efficacy of low-dose clozapine in PDP therapy and the
observation that atypical APDs appear to have several
advantages over the older typical agents led to the hypoth-
esis that selective 5-HT2A inverse agonist activity might be
an appropriate target mechanism to explore in a drug dis-
covery program [14]; thus we initiated a program to discover
novel 5-HT2A receptor inverse agonists.
A functional HTS R-SATTM assay for 5-HT2A inverse
agonists was configured by expression of the human 5-HT2A
human receptor in NIH 3T3 cells together with a marker
gene to permit signal detection using a colorimetric method.
A proprietary compound library of 130,000 chemically
diverse small molecules was screened in the HTS assay at a
concentration of 3 lM. Of the initial 500 hits, 100 were
characterized as potent 5-HT2A inverse agonists. Following
further screening for selectivity and subsequent lead opti-
mization, AC-90179 was identified as a selective 5-HT2A
inverse agonist [26]. It had nearly 100 fold selectivity for
5-HT2A receptors compared to 5-HT2B, 5-HT2C and 5-HT6
receptors as an inverse agonist. At concentrations less than
or equal to 1 lM, it did not interact with other monoamin-
ergic receptors. Although the oral bioavailability of AC-
90179 was very low, it was useful for initial proof of concept
studies in rodents. As expected, AC-90179 dose-depen-
dently eliminated head twitches induced by DOI, a behavior
mediated by 5-HT2A receptor stimulation. Also, AC-90179
inhibited MK-801-induced but not amphetamine-induced
locomotor activity. At the dose that effectively inhibited
MK-801-induced locomotor activity, AC-90179 did not
reduce spontaneous locomotor activity. Importantly, AC-
90179 was effective in restoring prepulse inhibition (PPI)
response disturbed by DOI. All these effects were expected
based on previous studies describing the pharmacology of
MDL-100,907, a selective 5-HT2A antagonist [27, 28].
The in vitro and in vivo pharmacology of AC-90179 was
attractive and, therefore, a major lead optimization effort
was launched to develop an orally bioavailable analogue
with similar pharmacology. This effort led to the discovery
of pimavanserin (ACP-103) [29], a molecule with similar
structural characteristics as AC-90179 but with much
greater oral bioavailability. Pimavanserin is an achiral
compound which is easy to synthesize in small or large
scale from readily available starting materials (Fig. 1).
Pimavanserin has no structural resemblance to the APDs.
Pimavanserin is a potent, selective 5-HT2A inverse ago-
nist, with selectivity over 5-HT2C receptors in binding and
functional assays and little to no activity at other GPCRs in
contrast to the available APDs (see Fig. 2; Table 1). Thus,
the structural characteristics and pharmacological selec-
tivity profile of pimavanserin differentiates it from typical
as well as atypical APDs.
Pimavanserin’s behavioral profile in rodents [29] is
consistent with that of other 5-HT2A antagonists like
AC-90179 and MDL-100,907. Thus, it blocks DOI-induced
head twitch and MK-801-induced hyperactivity. Addi-
tionally, it prevents DOI- and MK-801-induced disruptions
in prepulse inhibition. These behavioral effects are seen
with atypical APDs like risperidone, clozapine and que-
tiapine, which have appreciable antagonist activity at
5-HT2A receptors. However, unlike the APDs, pimavans-
erin lacks DA D2 antagonist activity and thus does not
show reliable, dose dependent blockade of amphetamine-
induced activity. Hence, pimavanserin shares several, but
not all of the preclinical behavioral characteristics observed
with atypical APDs.
In order to assess whether pimavanserin might be
effective in treating PDP, a rodent model of PD was
employed where rats received bilateral lesions of the sub-
stantia nigra (SN). Using this procedure, there was rapid
loss (within 1 day) of tyrosine hydroxylase, a marker of
healthy dopaminergic neurons, in the SN. Loss continued
until a maximal loss of roughly 75 % was reached around
2 weeks after lesion (Fig. 3). Notably, following SN lesion,
animals developed difficulty initiating and maintaining
motor behaviors, in a manner that was reversed by treat-
ment with L-DOPA. In addition to motor deficits, these
animals also displayed a psychosis-like pattern of behav-
ioral changes, i.e., they displayed changes in behaviors
typically used to assess the efficacy of antipsychotic
medications. These included increased numbers of spon-
2010 Neurochem Res (2014) 39:2008–2017
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taneous head twitches, augmented amphetamine-induced
hyperactivity and disrupted prepulse inhibition. Notably,
pimavanserin not only reversed the psychosis-like behav-
iors, but did so without augmenting motor problems or
blocking the ability of L-DOPA to improve motor behavior
(Fig. 3) [30]. The appearance of altered 5-HT2A-dependent
behaviors in lesioned rats is consistent with data demon-
strating that destruction of dopaminergic neurons in ani-
mals leads to adaptations in serotonergic signaling,
including increased extracellular 5-HT, increased serotonin
transporters, sprouting of serotonergic afferents to the
striatum an up-regulation of 5-HT2A mRNA in the striatum
[31–36].
Because the atypical APDs quetiapine and clozapine are
prescribed to PDP patients, we assessed whether these
compounds might also work in our animal model of PDP
and compared their in vivo profiles with that of pima-
vanserin [37]. Specifically, we assessed the dose of pima-
vanserin, clozapine and quetiapine required to reduce
psychosis-like rodent behaviors and the dose that caused
unwanted side effects like disruption of coordinated motor
behavior or sedation. In this manner a therapeutic ratio was
determined. All doses of quetiapine and most doses of
clozapine that were effective at blocking psychosis-like
behavior in bilaterally lesioned rats impaired motor
behavior. In contrast to clozapine and quetiapine, pima-
vanserin reduced psychosis-like behavior at doses more
than a hundred-fold lower than doses that reduced loco-
motion, and no dose of pimavanserin blocked D2-
Fig. 1 Two facile synthetic routes providing pimavanserin
Inverse agonist activity 
of Pimavanserin















Fig. 2 Inverse agonist activity of Pimavanserin. R-SATTM assays
were performed with 5-HT2A and 5-HT2C receptors as described [24]
using the indicated concentrations of Pimavanserin. Inverse agonist
activity was normalized to ritanserin (not shown)
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dependent motor behavior. Pimavanserin’s high therapeu-
tic ratio as assessed in these animal models suggests that it
may effectively treat symptoms of PDP without the risk for
concomitant loss of motor control and sedation commonly
seen with available atypical APDs.
Clinical Studies with Pimavanserin
Initial clinical studies in normal healthy volunteers showed
that pimavanserin was well tolerated in humans both when
given acutely and subchronically [38]. Nausea and vomit-
ing were considered to be dose-limiting following 14 days
of once daily oral dosing at 150 mg; 100 mg QD of pim-
avanserin given over the same period was therefore esti-
mated to be the maximum tolerated dose. Dose
proportional plasma exposure over a wide range of doses
was also observed in these studies. The half-life of pima-
vanserin was estimated to be between 55 and 60 h and no
high-fat food effect on bioavailability was observed [39].
Our rodent experiments demonstrated that pimavanserin
readily crosses the blood brain barrier and acts as a CNS-
active 5-HT2A inverse agonist. In order to investigate what
doses of pimavanserin that blocked the brain 5-HT2A
receptors in humans, we conducted a PET study in which
the 5-HT2A/5-HT2C/D2 ligand 11C-NMSP was used as the
radio ligand. The results showed that a dose of 10 mg of
pimavanserin was able to almost completely occupy the
brain 5-HT2A receptors in normal healthy volunteers [40].
Because 11C-NMSP is not a selective ligand, it predomi-
nantly labels DA D2 receptors in the striatum. Conse-
quently, and as expected based on the selectivity profile of
pimavanserin, we observed only minimal displacement of
11C-NMSP from striatum at doses as high as 100 mg. This
underlines the different pharmacology of pimavanserin
compared to that of all other APDs which interact with DA
receptors and numerous other targets.
Pimavanserin’s lack of interaction with DA D2 receptors
suggested that the it may be well tolerated in PDP patients
receiving DA replacement therapy, A double blind, pla-
cebo controlled safety study was therefore designed in
which 12 PD patients received placebo (N = 4), pima-
vanserin 25 mg (N = 4) or 100 mg (N = 4) once a day for
14 days [41]. The results suggested that pimavanserin was
safe and well tolerated by PD patients.
We then studied the ability of pimavanserin to reduce
psychosis in a Phase II study in patients with PDP. This
was a double blind randomized multi-center dose-escala-
tion study of 4 weeks duration that was designed to eval-
uate the safety and tolerability of pimavanserin as well as
its ability to attenuate PD psychosis [42]. Patients were
randomized to placebo (N = 31) or pimavanserin
(N = 29). They received 20 mg of pimavanserin (or
matching placebo) on day one and the daily dose could be
escalated to 40 or 60 mg on days 8 and 15, respectively,
based on the patients’ response to the therapy. Because of
Table 1 Receptor selectivity of pimavanserin compared to some antipsychotic drugs
Data are Ki values in nM derived from functional antagonist R-SATTM assays. –,not done; nr, no response
2012 Neurochem Res (2014) 39:2008–2017
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the long half-life of pimavanserin, steady state drug levels
were not likely reached until day 10–14. At Day 28, the
mean dose achieved for the pimavanserin arm was
44.8 mg, lower than the corresponding mean equivalent
dose of 55.9 mg in the placebo arm. This was likely a result
of better efficacy in the drug arm given that tolerability was
similar between the arms. The primary endpoint of the
study was motoric tolerability and, as expected,
Fig. 3 Altered tyrosine
hydroxylase
immunofluorescence and
behavior in animals with
bilateral lesions of the SN.
Colocalization (yellow) of
tyrosine hydroxylase (green)
and the neuronal marker
Neurotrace (red)
immunostaining in a sham
control (a) and lesioned animal
(b). On average, lesioned
animals showed a 75 %
reduction in TH
immunofluorescence 4 weeks
after lesion. Lesioned animals
displayed augmented
spontaneous head twitches (c),
augmented amphetamine-
induced locomotion (d) and
disrupted prepulse inhibition
(e) which were all reversed by
treatment with pimavanserin
Patient Pathway From Screening to Open-Label Treatment
6-Week Blinded Treatment Period Long-Term Open-Label












Pivotal Efficacy, Tolerability and Safety Study
Region North America
Patients 199, with moderate to severe PDP
Type of design Randomized, double-blind, placebo-controlled
Primary endpoint 9-item SAPS-PD; centralized ratings
Key secondary endpoint UPDRS Parts II and III
Fig. 4 Design of the pivotal
ACP-103-020 study [46]
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pimavanserin did not impair motor function compared to
placebo nor did it cause sedation or hypotension. In addi-
tion, pimavanserin showed good signals of effect on the
scale for assessment of positive symptoms (SAPS) hallu-
cinations and delusions domains (SAPS H ? D) and sig-
nificantly attenuated the psychosis as assessed by the
global item ratings of hallucinations (0.02) and delusions
(0.03) and was particularly effective in reducing persecu-
tory delusions (p = 0.009).
Based on these encouraging Phase II data, a large
international PDP study (ACP-103-012) was initiated. The
-012 study was a randomized (1:1:1), double blind, placebo
controlled study in which 298 patients with PDP received
placebo, 10 mg of pimavanserin or 40 mg of pimavanserin
once a day for 6 weeks. The primary endpoint was atten-
uation of psychosis as measured by the 20 item SAPS H?D
scale. Motoric tolerability compared to placebo was a key-
secondary endpoint. The -012 was the largest clinical study
conducted in PDP and though there were clear signals of
efficacy in the 40 mg arm, an unexpectedly large placebo
response (42 %) precluded statistical separation. The
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Fig. 5 Pimavanserin 40 mg
showed significant
improvements over multiple
endpoints measured in the ACP-
103-020 study [46]. The full
analysis set includes all patients
who received C1 dose and had a
SAPS assessment at baseline
and at least one afterwards. Data
points show least squares means
(SE)
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placebo on any measure. Importantly, both drug arms
confirmed the safety and motoric tolerability of pima-
vanserin in patients with PDP. For the 40 mg arm, addi-
tional benefits were suggested by improvements in
nighttime sleep (without daytime sedation) and reduction
in caregiver burden.
We had initiated a second large international PDP trial,
the ACP-103-014 study, before the outcome of the -012
study was known. This study had three arms; placebo, 10 and
20 mg of pimavanserin. Just as in the -012 study, SAPS H?D
was the primary endpoint and we intended to recruit 300
patients. The study was stopped early on the basis of the -012
study results and the similarities in design and lower doses
used. Despite the small sample size (N = 123), the 20 mg
arm showed numerical separation from the placebo arm but
did not achieve statistical significance.
A number of factors appeared to contribute to the high
placebo response in the -012 study and were taken into
account in the design of a new study, ACP-103-020 (Fig. 4)
[43]. The primary endpoint, the SAPS H?D scale, had been
assessed differently in the US and ex-US regions. Differences
in the efficacy profile were therefore prospectively analyzed
and showed a higher placebo response in the ex-US regions
where site-based raters were used. In the US, a small group of
well trained and independent raters interviewed patients and
caregivers via a live video link. This methodology provided
for lower variability and contributed to the stronger separation
of the 40 mg pimavanserin arm in the US. An additional
factor was that patients with milder symptoms had a larger
placebo response, thus only moderately or severely psychotic
PD patients were randomized to -020. Three additional design
enhancements included 1:1 randomization (placebo and
40 mg of pimavanserin) and a 2-week lead-in period in which
brief psychosocial therapy was offered [44]. This non-phar-
macologic therapy was used prior to randomization. In addi-
tion, the nine item SAPS-PD was used for the primary
endpoint, rather than the 20 item SAPS H?D. This optimized
scale was developed specifically for use in PDP and elimi-
nated items more specific to schizophrenia [45].
In the -020 study, pimavanserin demonstrated a highly
significant and clinically meaningful improvement on the
primary endpoint (Fig. 5a) [46]. As demonstrated in pre-
vious studies with pimavanserin in patients with PDP, the
drug candidate was safe and did not negatively impact the
motor control of the patients.
The effect on psychosis included significant improve-
ments on both hallucinations and delusions. As this study
was conducted entirely in North America, the SAPS-PD
was assessed solely by blinded, independent raters. In
addition, to the improvements on the centrally-rated SAPS-
PD, highly significant improvements on the investigator
assessed clinical global impression scale (Fig. 5b, c) and on
caregiver assessed burden (Fig. 5d) scores were observed.
Each of these was assessed independently such that the
different raters were blind to each other’s scores. In addi-
tion, and consistent with previously observed sleep benefits
in older healthy volunteers [47], patients reported highly
significant improvements in nighttime sleep and daytime
wakefulness using the SCOPA sleep instrument (Fig. 5e, f).
Patients who completed a blinded Phase III study had
the opportunity to roll into an open label extension study.
Analysis of long-term data from this study (collected up to
March 2013) showed continued safety and tolerability
compatible with long-term administration of the drug [48].
Future Directions
ACADIA is now focused on finalizing the Phase III PDP
program for NDA submission. Pimavanserin may also be
useful for treating psychotic conditions associated with
other neurodegenerative diseases and therefore a study in
Alzheimer’s disease psychosis (ADP) has recently been
initiated to explore this possibility. Another potential
opportunity may reside in schizophrenia therapy using
pimavanserin in combination with sub-therapeutic doses of
atypical antipsychotic agents in order to achieve efficacy
with an improved safety and tolerability profile, as sug-
gested by the outcome of a large Phase II study in acutely
psychotic schizophrenic patients [49].
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